LONDON, UK: Goodbody Health (AQSE: GDBY) announced the expansion of services through partnerships and the launch of its new mobile phlebotomy service to develop and increase the reach of the phlebotomy services that Goodbody is able to offer.
This allows testing to be undertaken in the patients home or other convenient location and meets the needs of those unable to travel. This has proven to be very successful with over 120 applicant phlebotomists for the platform and patients choosing this sample collection method. This sample collection method will be available for partners in the not-too-distant future. This is a significant piece of technology that has been developed over 4 months.
Following the Company announcement on January 26th, 2023 that it has partnered with Datar Cancer Genetics (Datar), a world-leading liquid biopsy company, to offer its innovative Circulating Tumour Cell (“CTC”) based multi-cancer screening solution Trucheck, the rollout of these innovative tests has started to show good progress.
The Company has had significant interest in the product through the initial soft-launch phase, demonstrating that this could be a significant revenue stream for the Company with 25 tests sold to date generating strong revenue. The Company has also established a distribution infrastructure to resell the tests to other private medical providers to drive additional volume and uptake has been positive.
Following the Company announcements on January 31st and February 15th, 2023 that the Company had signed phlebotomy contracts with 5 other testing suppliers who wish to use Goodbody Clinics as a phlebotomy partner, 4 more contracts have been signed with the following partners:
- Balance My Hormones – Hormone Replacement Provider
- Optimale – Hormone Replacement Provider
- Manual – Blood and Wellness Testing provider
- Cancer Screening Trust
George Thomas, Chief Executive Officer, said: “The Company is excited to develop new product opportunities, integrate with other providers and supply a more flexible mobile service. We believe this market will grow for all participants as UK health services delivery, including diagnostics, is delivered through partnerships and innovative third party solutions.”